登录

Dynasty Gene Raised Tens of Million Yuan Financing

作者: Mailman 2019-08-22 17:09
迪赢生物
http://www.dynastygene.com
企业数据由 动脉橙 提供支持
合成生物学研发与应用商 | 战略融资 | 运营中
中国-上海
2021-12-27
博裕资本
查看

On August 17th, the DNA synthesis technology company Dynasty Gene has completed tens of million yuan financing. This round of financing was led by Volcanics Venture.


Founded in January 2018, Dynasty Gene is an innovative high-tech company dedicated to the development and application of synthetic biology. 


Dynasty Gene has successfully developed the Micropore high-throughput DNA synthesis platform with independent intellectual property rights and the original QuarXeq double-stranded RNA probe capture technology. Based on them, it has launched a variety of products, including solutions of liquid biopsy Protocols, liquid-based probe capture and amplicon capture of various NGS library capture kits, probes, and oligonucleotide pool design synthesis services, as well as automated workstation solutions.


Mr. Zhang Mancang, CTO of Dynasty Gene, believes that synthetic biology is a high-tech discipline that leads the future. It has a wide range of applications, including high-throughput sequencing, artificial gene combination, DNA information storage, antibody optimization, and personalized tumor vaccines.


"We have covered many hospitals and third-party medical testing institutes, biomedical R&D companies and universities. We expect that by the end of 2019, the annual revenue scale will increase by 2 to 3 times," said Chen Yiqun, CEO of Dynasty Gene.


The team of Dynasty Gene consists of 9 doctors, 11 masters, and 9 undergraduate multidisciplinary young talents. According to 36kr, its chairman and chief scientist, Shi Yong, is a Distinguished/Tenure Professor of Shanghai Jiao Tong University, and a recipient of the National Science Fund for Outstanding Youth. Besides, other executives mainly graduate from high-ranking universities and have years of experience in the field of molecular biology.


"Our investment is based on two aspects. On the one hand, the team of Dynasty Gene was led by first-class scientists. On the other hand, the company had a clear application strategy," said Liu Kai, the vice president of Volcanics Venture.


>>>>

About Volcanics Venture


Volcanics Venture was founded in May 2016. It serves the most promising companies and outstanding entrepreneurs in internet innovation, intelligent technology, and the healthcare industry. 

相关赛道 IVD
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】点燃基因编辑领域新曙光,微光基因完成近亿元天使轮融资

【首发】Metanovas Biotech完成近千万美金天使轮融资,打造基于AI知识图谱的抗衰老产品体系

【首发】重磅!国际细胞外RNA研究第一人“引路” 艾码生物完成知名投资机构数千万天使轮投资核酸新药研发

【首发】普译生物完成数千万元天使轮融资,有望快速突破新一代基因测序卡脖子技术

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

FDA接受VX-445(Elexacaftor)、Tezacaftor和Ivacaftor组合疗法的新药申请

2019-08-22
下一篇

Yaoyanshe Completed 300 Million Yuan C Round of Financing

2019-08-22